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Abstract
AIM: To determine which baseline factors of chronic
hepatitis B patients are predictive of virological
response to Peginterferon a-2b therapy.
METHODS: A total of 21 HBeAg-positive chronic
hepatitis B (CHB) patients treated with Peginterferon
a-2b were recruited. They were treated with
Peginterferon a-2b (0.5-1.0 mg/kg per week) for
24 wk and followed up for 24 wk. Clinical and
laboratory data of the patients were determined at
pretreatment and at week 12, at 24 during treatment,
and at week 48 during follow up.
RESULTS: Ten patients achieved a virological response
at the end of treatment. Their baseline serum alanine
aminotransferase (ALT), thyroid-stimulating hormone
(TSH), and total thyroxin (TT4) levels were significantly
different from those who failed treatment. The positive
predictive values (PPV) and negative predictive values
(NPV) of ALT, TSH, and TT4 were 75% and 89 %, 75%
and 89 %, and 75% and 75%, respectively. Moreover,
combinations of the baseline ALT and TT4, ALT and
TSH, TT4 and TSH levels had much higher PPV and
NPV (86% and 88%, 89% and 100%, 83% and 100%,
respectively).

CONCLUSION: Baseline serum ALT, TSH, and TT4
levels, especially in combination, have high predictive
values of virological response to Peginterferon a-2b in
HBeAg-positive CHB patients.
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
Chronic hepatitis B virus (HBV) infection is a worldwide
health problem. More than 400 million people are
chronically infected with HBV and are at risk of
developing liver cirrhosis and hepatocellular carcinoma.
Each year more than one million people die from HBVrelated liver diseases[1-4].
At present, the two main categories of antiviral
drugs for chronic hepatitis B are interferon (including
Peginterferon) and nucleoside/nucleotide analogs.
Many studies have shown that an elevated serum
ALT level is associated with virological response and
HBeAg seroconversion in CHB patients [5-8]. Besides
higher serum ALT level, some studies also showed that
higher aspartate aminotransferase (AST) level, increased
histological activity in biopsy specimens, female sex,
and lower serum HBV DNA levels are associated with
a higher probability of HBeAg seroconversion in CHB
patients treated with interferon-based therapies[9-13]. It
is also reported that the HBV genotype is an important
predictor of response to interferon-based therapies[14-17].
Recently, serum HBeAg levels have been used as
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outcome predictors of sustained virological response
to Peginterferon a-2a in HBeAg-positive CHB patients
and showed high negative predictive values (NPVs) at
week 24 of therapy[18]. Another study showed that early
serum HBsAg drops also had high predictive values of
sustained virological response to Peginterferon a-2a in
HBeAg-negative chronic hepatitis B patients both at
week 12 and 24[19].
However, the predictive values of other factors,
especially the baseline factors for virological response
to Peginterferon a-2b therapy are not clear. Therefore,
in this study, we aimed to determine how well the
baseline factors predicted the virological response to
Peginterferon a-2b therapy in HBeAg-positive CHB
patients.

MATERIALS AND METHODS
Ethics
The study was approved by the Investigation and Ethics
Committee for Human Research at the Peking University
First Hospital (Beijing, China). All patients provided
informed written consent.
Patients and study design
Twenty-one consecutive HBeAg-positive chronic
hepatitis B patients were evaluated. Patients were treated
with Peginterferon a-2b at a dose of 0.5-1.0 mg/kg
per week for 24 wk. Clinical and laboratory data of the
patients were determined before treatment, at week
12, and 24 during treatment. Thereafter they were
scheduled for follow-up visits every 12 wk. End of
treatment (EOT) response was defined as more than
2 log10 IU/mL reduction in HBV DNA levels at the EOT.
Non-response was defined as less than 2 log10 IU/mL
reduction in HBV DNA levels at the EOT.
Measurement of serologic markers of HBV
HBsAg, antibody to HBsAg, HBeAg, antibody to HBeAg
and anti-HBc were measured using a microparticle
enzyme immunoassay (Abbott Laboratories, North
Chicago, IL). The HBV genotype was determined using
the INNO LiPA HBV genotyping assay. Serum HBV
DNA was measured using the TaqMan polymerase
chain reaction assay [COBAS TaqMan, Roche Molecular
System (lower limit of detection, 20 IU/mL)].
Measurement of biochemical markers
Alanine aminotransferase (ALT) and aspar tate
aminotransferase (AST) were measured using a Hitachi
Model 7600 Series Automatic Analyzer (Hitachi). Thyroidstimulating hormone (TSH), total triiodothyronine
(TT3), and total thyroxin (TT4) levels were measured
using a Centaur Automated Chemiluminescence
System (Bayer).
Statistical analysis
Quantitative variables were expressed as the median
with interquartile ranges (IQR), and categorical variables
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as frequencies. Comparisons between groups of
quantitative and qualitative variables were performed
using the Mann-Whitney U test and the Fisher’s exact
test, respectively. The accuracy of serum factors to
predict virological response was assessed using the
receiver operating characteristic curve. The cutoff
value was chosen according to the receiver operating
characteristic curve when the sensitivity and specificity
were both relatively high for the selective baseline factor.
All tests were two-sided and used a significance level of
0.05. Data handling and analysis were performed with
SPSS software for windows, version 13.0 (SPSS Inc.,
Chicago, IL).

RESULTS
Baseline characteristics of patients
The baseline characteristics of the 21 HBeAg-positive
CHB patients are shown in Table 1. The median age
was 25 years (range, 20-39), and 81% of them were male
(17/21). The median value of serum HBV DNA levels
was 8.2 log10 IU/mL (IQR, 7.5-8.7 log10 IU/mL). The
distribution of HBV genotype was: B, 24%; C, 76%. The
median values of serum ALT, AST, TSH, TT3, and TT4
level were 147 IU/L (IQR, 123-201 IU/L), 65 IU/L
(IQR, 51-97 IU/L), 2.06 mIU/L (IQR, 1.41-3.10 mIU/L),
2.22 nmol/L (IQR, 2.04-3.03 nmol/L), and 111.4 nmol/L
(IQR, 96.8-140.6 nmol/L) respectively. The baseline
TT3 and TT4 values of one patient were not assayed at
pretreatment. Serological tests were negative for hepatitis
C virus, hepatitis D virus, and human immunodeficiency
virus in all patients.
Virological response
Of the 21 patients, ten (48%) showed an EOT response,
and eleven (52%) were non-responders. Four patients
(19%) obtained HBeAg seroconversion at the end of
treatment (week 24). However, two of the four HBeAg
seroconversion patients lost anti-Hbe, while another
six patients achieved HBeAg seroconversion at week
48. The median value of serum HBV DNA levels were
2.7 log10 IU/mL (IQR, 1.9-4.0 log10 IU/mL) and 3.1
log10 IU/mL (IQR, 1.8-6.6 log10 IU/mL) in responders
at week 24 and 48 respectively. In non-responders,
The median value of serum HBV DNA levels were
7.4 log10 IU/mL (IQR, 6.8-7.9 log10 IU/mL) and 7.6
log10 IU/mL (IQR, 7.1-8.7 log10 IU/mL) at week 24
and 48 respectively. The baseline ALT and TT4 level
were significantly higher in responders than in nonresponders(both P < 0.05, Table 1). However, the
baseline TSH level was significantly lower in responders
than in non-responders(P < 0.05, Table 1). The baseline
age was similar between responders and non-responders.
Predictability
To determine how well the baseline ALT, TSH and TT4
levels predicted virological response to Peginterferon a-2b
therapy, we performed receiver operating characteristic
curves for each parameter. The areas under the curves of
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Table 1 Baseline characteristics of patients
Characteristic

All patients (n = 21)

Median age, range (yr)
Gender, male (%)
HBV genotype (%B, C)
Median HBV DNA levels, range [log (IU/mL)]
Median ALT level, range (IU/L)
Median AST level, range (IU/L)
Median TSH levels, range (mIU/L)
Median TT3 levels, range (nmol/L)
Median TT4 levels, range (nmol/L)

25 (20-39)
81
24, 76
8.2 (7.5-8.7)
147 (123-201)
65 (51-97)
2.06 (1.41-3.10)
2.22 (2.04-3.03)
111.4 (96.8-140.6)

Responders (n = 10)

Non-responders (n = 11)

P value

25 (20-38)
70
10, 90
7.7 (7.2-8.4)
184 (146-247)
90 (57-132)
1.82 (1.14-2.08)
2.85 (2.02-3.85)
132.7 (109.0-168.5)

25 (20-39)
91
36, 64
8.4 (8.1-8.8)
124 (112-148)
64 (45-73)
2.55 (1.68-4.11)
2.20 (2.02-2.54)
107.8 (88.4-117.3)

0.749
0.311
0.311
0.090
0.011a
0.072
0.035c
0.305
0.037e

Data are expressed as the median (IQR) and as percentages. HBV: Hepatitis B virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TSH:
Thyroid-stimulating hormone. aP < 0.05 differences of baseline serum ALT level between responders and non-responders; cP < 0.05 differences of baseline serum TSH level between responders and non-responders; eP < 0.05 differences of baseline serum TT4 level between responders and non-responders.

Table 2 Predictive value of single and combined baseline factors
Parameters
ALT ≥ 140
ALT < 140
TSH < 2.4
TSH ≥ 2.4
TT4 ≥ 120
TT4 < 120
ALT ≥ 140, TT4 ≥ 120
ALT < 140, TT4 < 120
ALT ≥ 140, TSH < 2.4
ALT < 140, TSH ≥ 2.4
TT4 ≥ 120, TSH < 2.4
TT4 < 120, TSH ≥ 2.4

Responders

Non-responders

Predictive
value (%)

9
1
9
1
6
3
6
1
8
0
5
0

3
8
3
8
2
9
1
7
1
6
1
7

PPV = 75
NPV = 89
PPV = 75
NPV = 89
PPV = 75
NPV = 75
PPV = 86
NPV = 88
PPV = 89
NPV = 100
PPV = 83
NPV = 100

Data are expressed as numbers of instances. PPV: Positive predictive
values; NPV: Negative predictive values.

ALT, TSH, and TT4 were 0.827 (P = 0.011), 0.773 (P =
0.035), and 0.778 (P = 0.037), respectively. Accordingly,
we chose cutoff values of 140 IU/L, 2.4 mIU/L, and
120 nmol/L for ALT, TSH, and TT4, respectively.
Correspondingly, their positive predictive values (PPV)
and negative predictive values (NPV) were 75% and 89 %,
75% and 89 %, and 75% and 75% (Table 2). We further
performed the combination of the baseline ALT and
TT4, ALT and TSH, and TT4 and TSH to predict the
virological response. We found that their PPV and NPV
were 86% and 88%, 89% and 100%, and 83% and 100%,
respectively (Table 2).

DISCUSSION
Nowadays, more and more doctors are taking the
initiative in individualized treatment for chronic hepatitis
B patients. With the purpose of taking individualized
treatment, it is important to evaluate the baseline status
of each patient at the start of treatment and to then
decide which antiviral drug is the best choice. For those
patients who are not likely to benefit from Peginterferon
a-2b therapy, an early switch to nucleoside/nucleotide
analogs is essential.
Recently, a study showed that HBeAg levels had
high negative predictive values (NPVs) at week 24 of

sustained virological response to Peginterferon a-2a
in HBeAg-positive CHB patients[18]. While in HBeAgnegative CHB patients, early serum HBsAg drops also
had high predictive values of sustained virological
response to Peginterferon a-2a at week 12 and 24[19].
In our study, 21 HBeAg-positive CHB patients were
treated with Peginterferon a-2b for 24 wk and followed
up for 24 wk. We found that baseline serum ALT, TSH,
and TT4 levels, and especially the combination of
these factors, had high predictive values of virological
response to Peginterferon a-2b therapy.
To identify the baseline predictors of virological
response, we performed univariate analysis and receiver
operating characteristic curves for baseline serum ALT,
TSH, and TT4 levels, and found that the cutoff value of
140 IU/L of baseline serum ALT level had a relatively
high predictive value of virological response. The
cutoff values for TSH and TT4 were 2.4 (mIU/L) and
120 (nmoI/L), respectively. Moreover, we found that
combinations of these factors could further improve the
PPV and NPV scores.
Some studies have shown that the rates of HBeAg
loss and seroconversion were correlated with the baseline
level of ALT. In patients with a higher baseline level
of ALT, the rates of HBeAg loss and seroconversion
during lamivudine therapy were also significantly higher
at the end of year three[7]. A previous study showed that
CHB patients with normal ALT levels respond very
poorly to interferon a-2a therapy. However, the response
was significantly better in patients with elevated ALT
levels[13]. In HBeAg-negative CHB patients treated with
Peginterferon a-2a, with or without lamivudine, a high
baseline ALT level was identified as a significant predictor
of virological response at weeks 24 post-treatment[8].
Besides high baseline serum ALT level, we also found
that higher TT4 level and lower baseline serum TSH level
were associated with better outcome of Peginterferon
a-2b therapy in HBeAg-positive CHB patients.
Although no study exploring the predictive value of
virological response for baseline serum TT4 in chronic
hepatitis B patients has been reported, several studies
have demonstrated a reciprocal relationship between the
endocrine and immune systems. Recently a study showed
that triiodothyronine and thyroxin concentrations were
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positively associated with markers of inflammation,
natural killer-like T cells, activated monocytes derived
interleukin-6 (IL-6), higher expression of IL-2 receptor
on CD3+ T-lymphocytes, and percentage expression of
memory T-lymphocytes, memory T-helper lymphocytes
and memory T-cytotoxic lymphocytes within normal
physiological ranges[20]. This is supported by previous
findings that thyroid hormone was involved in primary
and secondary lymphopoiesis, and blastogenic responses
to T and B cell mitogens were also enhanced following
thyroxin administration[21,22]. Other studies showed that
thyroxin did not induce resting T lymphocyte proliferation
but increased mitogen ConA-induced stimulation after
three days of culture, in a dose-dependent manner.
Thyroxin substitutive treatment restored the euthyroid
status and reversed the impairment of T-cell activation
induced by chronic stress in mice [23,24]. Interestingly,
the age-dependent immunological deterioration in
old mice could be recovered by thyroxin treatment[25].
These results indicated that thyroxin could enhance the
immune response. Thus, this may be the reason why the
responders who had higher baseline TT4 level achieved
virological response more easily during Peginterferon
a-2b therapy in our study.
Another major finding was the lower baseline TSH
level of responders was also associated with higher
virological response rate. This could be caused by
the negative feedback mechanism due to their higher
baseline serum TT4 level.
In conclusion, the identification and application
of baseline factors to predict virological response of
chronic hepatitis B patients before antiviral therapy is
important. Using this method, we can identify patients
who will most likely benefit from Peginterferon a-2b
therapy before treatment. However, because of the
small cohort of patients enrolled in our study, large-scale
studies are needed to further confirm our results and to
identify simpler and more appropriate factors that have
high predictive values of virological response in chronic
hepatitis B patients.

Terminology

ALT is an enzyme that is normally present in liver and heart cells. ALT is
released into blood when the liver or heart is damaged. TSH is a peptide
hormone synthesized and secreted by thyrotrope cells in the anterior pituitary
gland which regulates the endocrine function of the thyroid gland. Thyroxin
(T4) is a form of thyroid hormone which is the major hormone secreted by the
follicular cells of the thyroid gland.

Peer review

This study is of interest as it describes the relationship of virological response
to Peginterferon a-2b therapy and serum parameters at pretreatment, although
this was obtained in a very small cohort of patients.
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